Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.38 |
| ▸ | TACR1 | P25103 | 11/20 | 0.38 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.38 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.38 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.38 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15464199 | 0.94 | IDO1 (0.39) | IDO1PTPN1MRGPRX4TACR1CACNA1F | |
| SCHEMBL13723388 | 0.88 | MAOB (0.45) | IDO1PTPN1MAOB | |
| SCHEMBL13722536 | 0.87 | IDO1 (0.51) | IDO1MRGPRX4MAOB | |
| SCHEMBL4427337 | 0.80 | IDO1 (0.46) | IDO1TACR1CACNA1FCACNA1DCACNA1S | |
| SCHEMBL14060231 | 0.79 | MAOB (0.43) | IDO1MAOB | |
| SCHEMBL10743886 | 0.78 | MAOB (0.40) | MAOB | |
| SCHEMBL5415387 | 0.77 | MAPT (0.36) | IDO1 | |
| SCHEMBL13723108 | 0.75 | CCR5 (0.40) | IDO1MAOB | |
| SCHEMBL13723204 | 0.75 | SMN1; SMN2 (0.40) | — | |
| SCHEMBL13722701 | 0.75 | FFAR4 (0.42) | MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1870396-B1 | BENZYLOXYPROPYLAMINE DERIVATIVE | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2012-10-31 | — | — | EP | disclosed |
| US-20080262230-A1 | Benzyloxypropylamine Derivative | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262230-A1 | Benzyloxypropylamine Derivative | BDKRB2, BDKRB1, PNMT | IDO1 1680/4885PTPN1 3990/4885MRGPRX4 394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.